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ABSTRACT 
This study evaluated the effect of acetazolamide on thyroid-associated ophthalmopathy (TAO). Patients 
with a VISA classification index equal to or more than four were enrolled in the study and were randomly 
assigned into two groups. In both groups, treatment was initiated using prednisolone. Patients in the case 
group received acetazolamide tablets 250 mg daily in addition to prednisolone. Three months later, the 
VISA inflammatory score of patients in both groups were determined. Subsequent to intervention with 
acetazolamide, the VISA inflammatory score of patients in the case group were reduced as follows; orbital 
pain (57.1% versus 41.7%, P=0.736), eyelid edema (42.8% versus 27.1%, P=0.67), chemosis (53.3% versus 
33%, P=0.31), injection of the eyelids (60% versus 41.6%, P=0.342), and conjunctival injection (50% versus 
46.13%, P=0.73). However, these reductions were not statistically significant when compared with those 
observed in the control group (P=0.246). In conclusion, the effect of acetazolamide on all the parameters of 
the VISA inflammatory score was examined independently. All patients in the case group revealed a 
reduction in VISA inflammatory score following intervention. However, these reductions were not 
statistically significant. Further studies with large sample sizes are required. 
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INTRODUCTION 
Thyroid-associatedophthalmopathy (TAO) should be 
considered as an autoimmune inflammatory disorder, 
which is associated with Graves’ hyperthyroidism, 
Hashimoto’s thyroiditis, primary hypothyroidism, and 
euthyroidism with rates of approximately 90%, 3%, 1%, 
and 6%, respectively (1). Most patients with TAO reveal 
minimum symptoms, and only almost 4% determine 
significant clinical manifestations (2). Orbital fibroblasts 
play an essential role in the inflammatory process of 
TAO. Formation of specific surface receptors and 
expression of proinflammatory genes play an important 
role in this inflammatory process. During the 
inflammatory process of TAO, production of interleukin 6 
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and 8 and prostaglandin E2 increases the synthesis of 
hyaluronan glycosaminoglycan by approximately one 
hundred fold. This causes orbital fibroblasts and fat cells 
to change the connective tissue structure of the orbit (3). 
Ultimately, increased glycosaminoglycan accumulation 
sets off an increase of fluid retention in the orbital space 
(4), which increases the thickness of extraocular muscles, 
fat, retrobulbar, and connective tissue and results in 
fibrotic changes in the muscle (1-4). 
  On the other hand, TAO is classified according to activity 
or severity. Differentiation between severity and activity 
is imperative because each requires different treatments. 
Werner and NOSPECS classifications are based on disease 
severity, while Mouritis and VISA inflammatory score 
classifications are based on disease activity (5). According 
to the VISA classification, scoring of the findings are as 
follows (6,7): 
a. Orbital pain: painless orbit, 0; pain at rest, 2; pain 
when moving eyes, 1. 
b. Chemosis: chemosis that spreads beyond the gray line, 
2; chemosis that does not extend beyond the gray line, 1; 
absence of chemosis, 0. 
c. Eyelid edema: eyelid edema that does not change the 
superficial anatomy of eyelid and does not cause 
drooping or hanging disruption, 1; eyelid edema that 
results in changes in anatomy and hanging of the eyelid, 
2. 
d. Conjunctivalinjection: presence of conjunctival 
injection 1; absence of conjunctival congestion, 0. 
e. Eyelid injection: presence of eyelid injection, 1; 
absence of eyelid injection, 0. 
 
  Most patients with mild TAO only requireconservative 
treatment. In patients with moderate to severe active 
orbitopathyor optic nerve involvement, oral 
corticosteroids such as prednisolone 1mg/kg are 
recommended for 2-4 weeks until an appropriate 
response occurs, after which they are gradually tapered 
off the medication. If the VISA inflammatory score is less 
than 4, only conservative management is offered; 
however, if the score is more than four, treatment with 
prednisolone is recommended (7). If glycosaminoglycan 
accumulation occurs resulting in fluid retention, diuretics 
such as carbonic anhydrase inhibitors may prove 
beneficial for volume reduction in addition to 
corticosteroid compounds, which decrease inflammation 
(8). Since compounds such as acetazolamide are easily 
absorbed through the gastrointestinal tract, their 
maximum effects are achieved within 2 hours following 
consumption and persist for 12 hours following 
administration. Because these compounds are excreted 
through the kidneys and tubular secretion, their use 
should be restricted in patients with renal failure (9). As a 
matter of fact, there is a limited study on the 
effectiveness of acetazolamide on TAO; therefore, we 
planned to test this hypothesis in a tertiary referral 
center at Imam Khomeini Hospital, Jundishapur 
University of Medical Sciences (JUMS), Ahvaz, Iran. 
 
METHODS  
The inclusion criteria for this study were VISA 
inflammatory score more than 4, and the exclusion 
criteria were contraindication of acetazolamide or VISA 
inflammatory score less than 4. Informed consent was 
obtained and the protocol has been approved by the 
ethical committee of JUMS.  
  Both cases and controls were randomly assigned based 
on VISA inflammatory score.Twenty patients were each 
enrolled in the case group and in the control group, 
respectively. Patients were examined for eyelid edema, 
conjunctival and eyelid injection, proptosis, and visual 
acuity. Fundoscopy and intraocular pressure were 
checked in all patients. Patients with VISA inflammatory 
score more than 4 were randomly divided into two 
groups. Prednisolone was initiated in both groups, and 
acetazolamide tablets 250 mg daily in four divided doses 
were initiated in the case group. After three months, the   
of patients in both the groups were re-evaluated, and the 
scoring was performedaccordingly. 
 
RESULTS 
The mean age of patients in the control group was 
38.2±9.8 years while in case group was 42±10.2 years 
(P=0.212). In the control group, 6 (30%) patients were 
men and 14 (70%) were women; while in the case group, 
8 (40%) patients were men and 12 (60%) were women.  
  The effect of oral acetazolamide in the case group was 
evaluated in terms of changes in the VISA inflammatory 
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score. In the control group, the scoring criterion prior to 
treatment with prednisolone was 5.16±0.65 andfollowing 
three months of treatment with prednisolone was 
4.5±0.97. The VISA scoring system was used to determine 
the role of prednisolone in reducing inflammatory 
markers prior and after treatment. The results revealed a 
significant association between use of corticosteroids 
and inflammatory changes in the VISA scoring system 
(P=0.008). In the case group, the scoring average based 
on inflammatory indices before and after the 
intervention were 5.05±0.55 and 4.05±0.96, respectively. 
Although the use of acetazolamide decreased the VISA 
inflammatory score of patients in the case group, no 
significant difference was observed between the VISA 
inflammatory score of patients in the two groups (P=0. 
246). 
  In our study, we examined the effects of acetazolamide 
on each of the five inflammatory indices of the VISA 
scoring system. Three patients in the control group and 
six patients in the case group revealed improvement in 
eyelid edema. Although the rate of eyelid edema 
improvement in the case group was greater than that in 
the control group, the difference was not statistically 
significant (42.8% versus 27.1%, P=0.677). 
  Orbital pain improvement was reported in five (41.7%) 
patients in the control group and eight (57%. 1) patients 
in the case group. Although the degree of orbital pain 
improvement in the case group was greater than that in 
the control group, the difference was not statistically 
significant (P=0.736). 
  Conjunctivalchemosis was improved in four (33%) 
patients in the control group and eight (53.3%) patients 
in the case group. Even though the degree of 
improvement in conjunctivalchemosis in the case group 
was greater than that in the control group, the difference 
was not statistically significant (P=0.311). 
  Eyelidinjection was improved in five (41.6%) patients in 
the control group and nine (60%) patients in the case 
group. However, the degree of improvement was not 
significantly different between the two groups (P=0. 
342). Conjunctival injection was improved in six (46.1%) 
patients in the control group and seven patients in the 
case group (50%); however, the degree of improvement 
was not significantly different between the two groups 
(P=0. 736). 
DISCUSSION 
With regard to the pathogenesis of TAO due to fluid 
retention of hydrophilic materials such as hyaluronan 
glycosaminoglycan in the orbital space (6-9), in the study, 
acetazolamide had been administrated as a diuretic to 
reduce interstitial fluid. This study was designed to assess 
the hypothesis regarding effectiveness of acetazolamide 
on the active phase indices of TAO since limited research 
was found in this regard.  
  Although there are few reports revealed that 
acetazolamide may exacerbate thyrotoxicperiodic 
paralysis bouts (10,11), we did not record any 
acetazolamide related side effects in our follow up. 
However it is pertinent to follow the cases in a longer 
duration. 
In our study, the effect of acetazolamide on all the 
parameters of the VISA inflammatory score was 
examined. Recovery and decrease in the VISA 
inflammatory score following the intervention was noted 
in most subjects; however, no significant differences 
were observed between the two groups with respect to 
the reduction in VISA inflammatory score. Although the 
results obtained from the control group in the context of 
the effectiveness of prednisone in the inflammatory 
phase of TAO reduced the VISA inflammatory score, 
inflammatory indices were statistically significant 
(P=0.008). When comparing the case and control groups 
in terms of acetazolamide intervention during the three-
month period revealed no significant differences 
(P=0.246),  the reduction in the VISA inflammatory score 
was greater in the case group.  
  Our limitations included low incidence of TAO and small 
sample size, therefore similar studies with a larger 
sample size, longer duration of the active phase of TAO, 
and non-inflammatory side effects are necessary in order 
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